BACKGROUND: Recurrent hepatitis C virus (HCV) has been a serious problem after liver transplantation (LT). We report our experience of 24-week therapy with sofosbuvir (SOF) and ribavirin (RBV) in post-LT recurrent HCV in living donor liver transplantation (LDLT) setting in South Asia. METHODS: Data from all patients treated for post-transplantation HCV recurrence in a single center were analyzed. Treatment regimen was 24 weeks of SOF 400 mg daily and RBV (starting at 800 mg daily, increased as tolerated). Sustained virological response (SVR) was assessed 12 weeks and 24 weeks after completion of treatment. RESULTS: 63 patients (median age 52 [range 30-69] years; 80% males) were treated. Most (76.2%) were treatment experienced and predominant HCV genotype was 3 (77.7%) followed by 1 (20.6%). Median transient elastography (Fibroscan) score was 7 (range 3-11) kPa and none of the patients had cirrhosis. SVR12 was achieved in 60 of 63 patients (95.2%) while SVR24 was noted in 59 (93.7%). SVR12 rates were as good in genotype-3 as in genotype-1. Older age, longer period after transplantation, higher Fibroscan value and higher need for erythropoietin were likely to be associated with relapse. Adverse effects were noted in 34 patients and weakness and fatigue were the commonest side effects. Significant drop in hemoglobin (<8 g/dL) was seen in 6 patients. CONCLUSIONS: SOF + RBV combination therapy for 24 weeks was safe and effective in treatment of for post-LT recurrent HCV in a single LT center and remains relevant due to its low cost and lack of drug interactions.
BACKGROUND: Recurrent hepatitis C virus (HCV) has been a serious problem after liver transplantation (LT). We report our experience of 24-week therapy with sofosbuvir (SOF) and ribavirin (RBV) in post-LT recurrent HCV in living donor liver transplantation (LDLT) setting in South Asia. METHODS: Data from all patients treated for post-transplantation HCV recurrence in a single center were analyzed. Treatment regimen was 24 weeks of SOF 400 mg daily and RBV (starting at 800 mg daily, increased as tolerated). Sustained virological response (SVR) was assessed 12 weeks and 24 weeks after completion of treatment. RESULTS: 63 patients (median age 52 [range 30-69] years; 80% males) were treated. Most (76.2%) were treatment experienced and predominant HCV genotype was 3 (77.7%) followed by 1 (20.6%). Median transient elastography (Fibroscan) score was 7 (range 3-11) kPa and none of the patients had cirrhosis. SVR12 was achieved in 60 of 63 patients (95.2%) while SVR24 was noted in 59 (93.7%). SVR12 rates were as good in genotype-3 as in genotype-1. Older age, longer period after transplantation, higher Fibroscan value and higher need for erythropoietin were likely to be associated with relapse. Adverse effects were noted in 34 patients and weakness and fatigue were the commonest side effects. Significant drop in hemoglobin (<8 g/dL) was seen in 6 patients. CONCLUSIONS:SOF + RBV combination therapy for 24 weeks was safe and effective in treatment of for post-LT recurrent HCV in a single LT center and remains relevant due to its low cost and lack of drug interactions.
Entities:
Keywords:
CBC, complete blood counts; DAA, directly acting antivirals; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; Hb%, hemoglobin; KFT, kidney function tests; LDLT, living donor liver transplantation; LFT, liver function tests; LT, liver transplantation; RBV, ribavirin; SOF, sofosbuvir; SVR, sustained virological response; g/dL, grams per decilitre; genotype-1; genotype-3; kPA, kilo pascals; living donor liver transplantation; recurrent hepatitis C; sustained viral response
Authors: Michael Manns; Didier Samuel; Edward J Gane; David Mutimer; Geoff McCaughan; Maria Buti; Martín Prieto; José Luis Calleja; Markus Peck-Radosavljevic; Beat Müllhaupt; Kosh Agarwal; Peter Angus; Eric M Yoshida; Massimo Colombo; Mario Rizzetto; Hadas Dvory-Sobol; Jill Denning; Sarah Arterburn; Phillip S Pang; Diana Brainard; John G McHutchison; Jean-François Dufour; Hans Van Vlierberghe; Bart van Hoek; Xavier Forns Journal: Lancet Infect Dis Date: 2016-02-18 Impact factor: 25.071
Authors: M Prieto; M Berenguer; J M Rayón; J Córdoba; L Argüello; D Carrasco; A García-Herola; V Olaso; M De Juan; M Gobernado; J Mir; J Berenguer Journal: Hepatology Date: 1999-01 Impact factor: 17.425
Authors: Xavier Forns; Michael Charlton; Jill Denning; John G McHutchison; William T Symonds; Diana Brainard; Theo Brandt-Sarif; Paul Chang; Valerie Kivett; Lluís Castells; Martín Prieto; Robert J Fontana; Thomas F Baumert; Audrey Coilly; Maria Carlota Londoño; François Habersetzer Journal: Hepatology Date: 2015-03-20 Impact factor: 17.425
Authors: Sammy Saab; Adam Greenberg; Edwin Li; Sherona Ngashea Bau; Francisco Durazo; Mohammed El-Kabany; Steven Han; Ronald W Busuttil Journal: Liver Int Date: 2015-05-12 Impact factor: 5.828
Authors: Michael Charlton; Edward Gane; Michael P Manns; Robert S Brown; Michael P Curry; Paul Y Kwo; Robert J Fontana; Richard Gilroy; Lewis Teperman; Andrew J Muir; John G McHutchison; William T Symonds; Diana Brainard; Brian Kirby; Hadas Dvory-Sobol; Jill Denning; Sarah Arterburn; Didier Samuel; Xavier Forns; Norah A Terrault Journal: Gastroenterology Date: 2014-10-07 Impact factor: 22.682
Authors: Kurinchi Selvan Gurusamy; Emmanuel Tsochatzis; Clare D Toon; Brian R Davidson; Andrew K Burroughs Journal: Cochrane Database Syst Rev Date: 2013-12-02
Authors: Massimo Giuseppe Colombo; Erkin Isakovich Musabaev; Umed Yusupovich Ismailov; Igor A Zaytsev; Alexander V Nersesov; Igor Anatoliyevich Anastasiy; Igor Alexandrovich Karpov; Olga A Golubovska; Kulpash S Kaliaskarova; Ravishankar Ac; Sanjay Hadigal Journal: World J Gastroenterol Date: 2019-08-07 Impact factor: 5.742